ArticleClinical science (London, England : 1979)2020
Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.
Article in Clinical science (London, England : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies.Stem cell reviews and reports · 2024Pooled it
- Mesenchymal stem cell derived exosomes mitigate COVID-19 cytokine storm via Annexin A1 and TGF-β mediated MAPK pathway inhibition.Stem cell research & therapy · 2026Article
- Extracellular vesicles decoying across host immunity.Journal of leukocyte biology · 2025Review
- Extracellular vesicles: Antiviral functions and applications in therapeutics and vaccines.iScience · 2025Review
- Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention.Fundamental research · 2025Review
- Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Exosomes and SARS-CoV-2 infection.Frontiers in immunology · 2024Review
- The Long Journey of Extracellular Vesicles towards Global Scientific Acclamation.Advanced pharmaceutical bulletin · 2023Review
- Review
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.Acta pharmaceutica Sinica. B · 2023Review
- Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability.Frontiers in immunology · 2023Article
- Coagulation potential and the integrated omics of extracellular vesicles from COVID-19 positive patient plasma.Scientific reports · 2022Article
- The importance of activated TMPRSS2 in the proviral role of small extracellular vesicles in SARS-CoV-2 infection.Journal of extracellular vesicles · 2022Article
- Increased circulating microparticles contribute to severe infection and adverse outcomes of COVID-19 in patients with diabetes.American journal of physiology. Heart and circulatory physiology · 2022Article
- Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.International journal of molecular sciences · 2022Review
- Post-COVID-19 Parkinsonism and Parkinson's Disease Pathogenesis: The Exosomal Cargo Hypothesis.International journal of molecular sciences · 2022Review
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.Science advances · 2022Article
- Application of exosomes for the alleviation of COVID-19-related pathologies.Cell biochemistry and function · 2022Review
- Role of extracellular vesicles in severe pneumonia and sepsis.Expert opinion on biological therapy · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel strain of coronavirus that appeared in 2019, SARS-CoV-2, is the causative agent of severe respiratory disease, COVID-19, and the ongoing pandemic. As for SARS-CoV that caused the SARS 2003 epidemic, the receptor on host cells that promotes uptake, through attachment of the spike (S) protein of the virus, is angiotensin-converting enzyme 2 (ACE2). In a recent article published by Batlle et al. (Clin. Sci. (Lond.) (2020) 134, 543-545) it was suggested that soluble recombinant ACE2 could be used as a novel biological therapeutic to intercept the virus, limiting the progression of infection and reducing lung injury. Another way, discussed here, to capture SARS-CoV-2, as an adjunct or alternative, would be to use ACE2+-small extracellular vesicles (sEVs). A competitive inhibition therapy could therefore be developed, using sEVs from engineered mesenchymal stromal/stem cells (MSCs), overexpressing ACE2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.